“Hey kids, let’s put on a show!” That was a famous line from the 1937 Broadway musical, Babes in Arms, shouted to exhort the old gang to take action to save the orphanage. As the theater market just put on…
Category Archives: Reimbursement
He Said What?!?! Best Biotech Quotes of 2011
December 29, 2011 – 3:26 pm
As BioWorld Insight readers know, our “Word on the Street” column provides a sample of the most entertaining and thought-provoking quotes our staff stumbles upon each week. Some are gathered during interviews, some gleaned from analyst reports, and some overheard…
Can Other Cell Therapy Firms Avoid Dendreon’s Fate?
December 7, 2011 – 5:43 pm
Stem cell therapies may be relatively early stage, but that hasn’t stopped their developers from giving some serious thought to late stage issues like reimbursement and health economics.
A Little Bit of Certainty Could Go a Long Way
September 23, 2011 – 11:19 am
Regulatory certainty. It’s something industry needs and investors want to see. It’s also one of the drivers for job creation. But it’s something our government doesn’t seem to get.
Unless it’s Affordable, Curing Cancer is Just a Dream
August 30, 2011 – 12:43 pm
Although they’re the stuff of science, statistics too often lack the power to move us. After all, they’re just numbers. So when companies like Dendreon Corp. and Seattle Genetics Inc. price their cancer treatments at nearly $100,000 or more, we…
Biopharmas Should Explore Better Ways to Make and Regulate Drugs to Avoid Shortages
August 10, 2011 – 3:36 pm
What’s causing drug shortages in the U.S., and is it a matter of mechanisms of control or methods of drug production? In 2010, there were shortages of 178 drugs in the U.S., a record-high level. Many drugs on the 2010…
Don’t Price Drugs on What the Market Used to Bear
August 9, 2011 – 9:52 am
All those warnings about price pressures and reimbursement woes – they didn’t come from Chicken Little. The sky really could be falling for drugmakers that insist on pricing their products based on what the market used to bear.
The Scariest Thing about Dendreon’s Implosion
August 4, 2011 – 1:37 pm
As a biotech junkie, I’ll admit I was shocked to the core by Dendreon Corp.’s second-quarter admission that prostate cancer vaccine Provenge (Sipuleucel-T) is thus far not succeeding commercially.
Join the Conversation